Sign in

CIK 0001501989

  • Accelerated filer

CytomX Therapeutics, Inc.

Sign in to watch
Ticker
CTMX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
273521219
Phone
+1 650-515-3185
Business address
151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Option exercise CEO acquired 109,768 shares (option exercise)
  4. 4 Derivatives Options or other derivatives
  5. 3 Insider Initial Statement of Ownership
  6. 4 Open-market sale General Counsel sold 5,268 shares at $2.09 ($10,986)
  7. 4 Open-market sale CEO sold 20,223 shares at $2.09 ($42,175)
  8. 4 Open-market sale SVP, Finance and Accounting sold 2,971 shares at $2.09 ($6,196)
  9. 4 Open-market sale SVP, Chief Scientific Officer sold 12,795 shares at $2.09 ($26,684)
  10. 4 Open-market sale Chief Business Officer sold 6,562 shares at $2.09 ($13,685)
  11. 4 Grant or award CEO acquired 90,000 shares (grant or award)
  12. 4 Grant or award General Counsel acquired 25,000 shares (grant or award)
  13. 4 Grant or award SVP, Finance and Accounting acquired 40,000 shares (grant or award)
  14. 4 Grant or award Chief Business Officer acquired 30,000 shares (grant or award)
  15. 4 Grant or award SVP, Chief Scientific Officer acquired 26,250 shares (grant or award)
  16. 4 Grant or award Chief Medical Officer acquired 26,250 shares (grant or award)
  17. 4 Open-market sale CEO sold 13,551 shares at $1.38 ($18,710)
  18. 4 Open-market sale SVP, Chief Scientific Officer sold 4,077 shares at $1.38 ($5,628)
  19. 4 Open-market sale Chief Business Officer sold 4,077 shares at $1.38 ($5,628)
  20. 4 Open-market sale General Counsel sold 4,077 shares at $1.38 ($5,629)

Page 4 of 20 · 400 filings